- Home
- MPU vs QNCX Comparison
MPU vs QNCX Comparison
Compare MPU & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | QNCX |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 19.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MPU | QNCX |
|---|---|---|
| Price | $0.33 | $0.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.2M | 581.6K |
| Earning Date | 04-16-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.08 |
| 52 Week High | $4.44 | $4.55 |
Technical Indicators
Market Signals| Indicator | MPU | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 44.77 |
| Support Level | $0.21 | $0.79 |
| Resistance Level | $0.75 | $0.98 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 19.30 | 25.24 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Corp is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.